manilatimes

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

- First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong collaboration with Japanese regulators and clinical societies - ...
Nasdaq

Alpha Tau Medical Ltd. Reports Promising Interim Results for Alpha DaRT® in Pancreatic Cancer Trials and Achieves Key Regulatory Milestones

Alpha Tau Medical Ltd. announced significant advancements in their alpha-radiation cancer treatment, Alpha DaRT®, during the 2025 ASCO GI Symposium and R&D Update Day. Interim results from three ...
Nasdaq

Alpha Tau Medical Reports Strong Interim Clinical Data for Alpha DaRT® in Pancreatic Cancer and Other Tumors

Alpha Tau reports promising Alpha DaRT trial results in pancreatic cancer and head and neck cancer, with significant survival benefits. High disease control rate (91% DCR) and positive interim safety ...
Business Insider

Buy Rating on Alpha Tau Medical Ltd. Amidst Promising Alpha DaRT Cancer Treatment Trials and Solid Financials

Ashiq Mubarack, an analyst from Citi, has initiated a new Buy rating on Alpha Tau Medical Ltd (DRTS). Ashiq Mubarack has given his Buy rating due to a combination of factors surrounding the potential ...